| Symbol | RDGL |
|---|---|
| Name | VIVOS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 99336 United States WA 1030 N Center Parkway |
| Telephone | (509) 222-2222 |
| Fax | — |
| — | |
| Website | http://www.radiogel.com |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Fruci & Associates II, PLLC; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001449349 |
| Description | Vivos Inc developed a Y-90 brachytherapy product called Precision Radionuclide TherapyTM. It is designated as "Breakthrough" by the FDA. There is an ongoing clinical trial in humans in India and multiply animal therapies for horses, dogs, cats, and exotics in a growing number of certified clinics across the United States. Additional info from OTC: |
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
Read moreVivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing
Read moreVivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
Read moreNew Form 1-A/A - VIVOS INC <b>Filed:</b> 2026-03-04 <b>AccNo:</b> 0001493152-26-008813 <b>Size:</b> 2 MB
Read moreVivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
Read moreKorenko Michael K 🟢 acquired 200.0K shares of VIVOS INC (RDGL) at $0.06 Transaction Date: Dec 31, 2025 | Filing ID: 000002
Read moreKorenko Michael K 🟢 acquired 100.0K shares of VIVOS INC (RDGL) at $0.07 Transaction Date: Dec 02, 2025 | Filing ID: 000006
Read moreKorenko Michael K 🟢 acquired 100.0K shares of VIVOS INC (RDGL) at $0.06 Transaction Date: Nov 20, 2025 | Filing ID: 000004
Read more